BACKGROUND: An unmet clinical need in Parkinson's disease (PD) is to identify biomarkers for diagnosis, preferably in peripherally accessible tissues such as skin. Immunohistochemical studies have detected pathological α-synuclein (αSyn) in skin biopsies from PD patients albeit sensitivity needs to be improved. OBJECTIVE: Our study provides the ultrasensitive detection of pathological αSyn present in the skin of PD patients, and thus, pathological αSyn in skin could be a potential biomarker for PD. METHODS: The real-time quaking-induced conversion assay was used to detect pathological αSyn present in human skin tissues. Further, we optimized this ultra-sensitive and specific assay for both frozen and formalin-fixed paraffin-embedded sections of skin tissues. We determined the seeding kinetics of the αSyn present in the skin from autopsied subjects consisting of frozen skin tissues from 25 PD and 25 controls and formalin-fixed paraffin-embedded skin sections from 12 PD and 12 controls. RESULTS: In a blinded study of skin tissues from autopsied subjects, we correctly identified 24/25 PD and 24/25 controls using frozen skin tissues (96% sensitivity and 96% specificity) compared to 9/12 PD and 10/12 controls using formalin-fixed paraffin-embedded skin sections (75% sensitivity and 83% specificity). CONCLUSIONS: Our blinded study results clearly demonstrate the feasibility of using skin tissues for clinical diagnosis of PD by detecting pathological αSyn. Moreover, this peripheral biomarker discovery study may have broader translational value in detecting misfolded proteins in skin samples as a longitudinal progression marker.
BACKGROUND: An unmet clinical need in Parkinson's disease (PD) is to identify biomarkers for diagnosis, preferably in peripherally accessible tissues such as skin. Immunohistochemical studies have detected pathological α-synuclein (αSyn) in skin biopsies from PDpatients albeit sensitivity needs to be improved. OBJECTIVE: Our study provides the ultrasensitive detection of pathological αSyn present in the skin of PDpatients, and thus, pathological αSyn in skin could be a potential biomarker for PD. METHODS: The real-time quaking-induced conversion assay was used to detect pathological αSyn present in human skin tissues. Further, we optimized this ultra-sensitive and specific assay for both frozen and formalin-fixed paraffin-embedded sections of skin tissues. We determined the seeding kinetics of the αSyn present in the skin from autopsied subjects consisting of frozen skin tissues from 25 PD and 25 controls and formalin-fixed paraffin-embedded skin sections from 12 PD and 12 controls. RESULTS: In a blinded study of skin tissues from autopsied subjects, we correctly identified 24/25 PD and 24/25 controls using frozen skin tissues (96% sensitivity and 96% specificity) compared to 9/12 PD and 10/12 controls using formalin-fixed paraffin-embedded skin sections (75% sensitivity and 83% specificity). CONCLUSIONS: Our blinded study results clearly demonstrate the feasibility of using skin tissues for clinical diagnosis of PD by detecting pathological αSyn. Moreover, this peripheral biomarker discovery study may have broader translational value in detecting misfolded proteins in skin samples as a longitudinal progression marker.
Authors: Thomas G Beach; Charles H Adler; Lucia I Sue; Geidy Serrano; Holly A Shill; Douglas G Walker; LihFen Lue; Alex E Roher; Brittany N Dugger; Chera Maarouf; Alex C Birdsill; Anthony Intorcia; Megan Saxon-Labelle; Joel Pullen; Alexander Scroggins; Jessica Filon; Sarah Scott; Brittany Hoffman; Angelica Garcia; John N Caviness; Joseph G Hentz; Erika Driver-Dunckley; Sandra A Jacobson; Kathryn J Davis; Christine M Belden; Kathy E Long; Michael Malek-Ahmadi; Jessica J Powell; Lisa D Gale; Lisa R Nicholson; Richard J Caselli; Bryan K Woodruff; Steven Z Rapscak; Geoffrey L Ahern; Jiong Shi; Anna D Burke; Eric M Reiman; Marwan N Sabbagh Journal: Neuropathology Date: 2015-01-26 Impact factor: 1.906
Authors: Neha Prakash; Chelsea Caspell-Garcia; Christopher Coffey; Andrew Siderowf; Caroline M Tanner; Karl Kieburtz; Brit Mollenhauer; Douglas Galasko; Kalpana Merchant; Tatiana Foroud; Lana M Chahine; Daniel Weintraub; Cindy Casaceli; Ray Dorsey; Renee Wilson; Margaret Herzog; Nichole Daegele; Vanessa Arnedo; Mark Frasier; Todd Sherer; Ken Marek; Samuel Frank; Danna Jennings; Tanya Simuni Journal: Parkinsonism Relat Disord Date: 2019-01-31 Impact factor: 4.891
Authors: Brit Mollenhauer; Richard Batrla; Omar El-Agnaf; Douglas R Galasko; Hilal A Lashuel; Kalpana M Merchant; Lesley M Shaw; Dennis J Selkoe; Robert Umek; Hugo Vanderstichele; Henrik Zetterberg; Jing Zhang; Chelsea Caspell-Garcia; Chris Coffey; Samantha J Hutten; Mark Frasier; Peggy Taylor Journal: Mov Disord Date: 2017-07-22 Impact factor: 10.338
Authors: Ildefonso Rodriguez-Leyva; Erika Chi-Ahumada; Manuel Mejía; Juan P Castanedo-Cazares; William Eng; Sami K Saikaly; Juan Carrizales; Todd D Levine; Robert A Norman; Maria E Jimenez-Capdeville Journal: Mov Disord Clin Pract Date: 2017-06-01
Authors: V Donadio; A Incensi; O El-Agnaf; G Rizzo; N Vaikath; F Del Sorbo; C Scaglione; S Capellari; A Elia; M Stanzani Maserati; R Pantieri; R Liguori Journal: Sci Rep Date: 2018-09-24 Impact factor: 4.379
Authors: Moriah R Arnold; David G Coughlin; Barbara H Brumbach; Denis S Smirnov; Luis Concha-Marambio; Carly M Farris; Yihua Ma; Yongya Kim; Edward N Wilson; Jeffrey A Kaye; Annie Hiniker; Randy L Woltjer; Doug R Galasko; Joseph F Quinn Journal: Ann Neurol Date: 2022-07-29 Impact factor: 11.274
Authors: Eino Solje; Alberto Benussi; Emanuele Buratti; Anne M Remes; Annakaisa Haapasalo; Barbara Borroni Journal: Diagnostics (Basel) Date: 2021-04-27
Authors: Risa Isonaka; David S Goldstein; William Zhu; Esther Yoon; Debra Ehrlich; Alice B Schindler; Angela D Kokkinis; Marya S Sabir; Sonja W Scholz; Sara Bandres-Ciga; Cornelis Blauwendraat; Pedro Gonzalez-Alegre; Grisel Lopez; Ellen Sidransky; Derek P Narendra Journal: Mov Disord Date: 2021-06-02 Impact factor: 9.698